The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 studies of DZD8586 in CLL/SLL patients after covalent or non-covalent BTK inhibitors and BTK degraders.
 
Jianyong Li
No Relationships to Disclose
 
Ke-Shu Zhou
No Relationships to Disclose
 
Huayuan Zhu
No Relationships to Disclose
 
Sujun Gao
No Relationships to Disclose
 
Tingyu Wang
No Relationships to Disclose
 
Jian-Qing Mi
No Relationships to Disclose
 
Xutao Guo
No Relationships to Disclose
 
Kaiyang Ding
No Relationships to Disclose
 
Guohui Cui
No Relationships to Disclose
 
Wei Yang
No Relationships to Disclose
 
Rui Huang
No Relationships to Disclose
 
Lihua Qiu
No Relationships to Disclose
 
Geoffrey Chong
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene (Inst); Regeneron (Inst); Takeda (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dizal Pharma (Inst); Dizal Pharma (Inst); Hutchison MediPharma (Inst); Incyte (Inst); Innate Pharma (Inst); Isofol Medical (Inst); Merck Serono (Inst); MorphoSys (Inst); Pharmacyclics (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst)
 
Mark Geyer
Consulting or Advisory Role - Bioheng; Jazz Pharmaceuticals; Sanofi; Takeda
Research Funding - Actinium Pharmaceuticals (Inst); Amgen (Inst); Sanofi; Tigen Pharma
Travel, Accommodations, Expenses - Takeda
 
Wuhan Hui
No Relationships to Disclose
 
Yun Zhuang
No Relationships to Disclose
 
Hongmei Jing
No Relationships to Disclose
 
Ying Xiang
No Relationships to Disclose
 
Ke Fang
Employment - Dizal Pharma
 
Chan Cheah
Honoraria - AstraZeneca (Inst); BeiGene (Inst); crispr therapeutics; Dizal Pharma (Inst); Gilead Sciences; Janssen-Cilag (Inst); Loxo/Lilly; Menarini (Inst); Novartis; Roche/Genentech (Inst); SOBI; TG Therapeutics
Consulting or Advisory Role - AstraZeneca; BeiGene (Inst); Dizal Pharma (Inst); Gilead Sciences; Janssen-Cilag; Kite, a Gilead company (Inst); Loxo/Lilly; Menarini (Inst); Roche/Genentech (Inst)
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - BeiGene; Lilly; Roche